OrbiMed

OrbiMed traces its roots to the 1989 research firm Mehta & Isaly and was formed under its current name in 1998 (Wikipedia). Its homepage says it has been 'investing globally for over 25 years' from early-stage private companies to large multinationals and that its team of over 150 'manages approximately $20 billion across public and private company investments worldwide'. It runs venture, private equity, public equity and royalty strategies, with regional teams for North America, Europe and Asia. Oncology companies on its portfolio page include Adcendo (tissue-factor antibody-drug conjugates), Adela (blood-based cancer detection by methylation), Adicet Bio (universal immune-cell therapies for cancer), Alentis Therapeutics (Claudin-1 antibodies and ADCs), Alpheus Medical (sonodynamic therapy for glioblastoma) and Alterome Therapeutics (alteration-specific precision oncology). Treeline Biosciences is featured on the homepage.